These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36645632)

  • 21. Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.
    Ma L; Zhang G; Miao XB; Deng XB; Wu Y; Liu Y; Jin ZR; Li XQ; Liu QZ; Sun DX; Testa JR; Yao KT; Xiao GH
    FEBS J; 2013 May; 280(9):2027-41. PubMed ID: 23461856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.
    Luo F; Lu FT; Qiu MZ; Zhou T; Ma WJ; Luo M; Zeng KM; Luo QY; Pan WT; Zhang L; Xia ZF; Zhang ZH; Cao JX; Zhao HY; Zhang L; Yang DJ
    Cell Death Dis; 2021 Aug; 12(8):772. PubMed ID: 34354046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBV-associated nasopharyngeal carcinoma.
    Man CH; Wei-Man Lun S; Wai-Ying Hui J; To KF; Choy KW; Wing-Hung Chan A; Chow C; Tin-Yun Chung G; Tsao SW; Tak-Chun Yip T; Busson P; Lo KW
    J Pathol; 2012 Feb; 226(3):471-81. PubMed ID: 22009689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma.
    Xue Z; Lui VWY; Li Y; Jia L; You C; Li X; Piao W; Yuan H; Khong PL; Lo KW; Cheung LWT; Lee VHF; Lee AWM; Tsao SW; Tsang CM
    J Exp Clin Cancer Res; 2020 Nov; 39(1):262. PubMed ID: 33243298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TIMELESS confers cisplatin resistance in nasopharyngeal carcinoma by activating the Wnt/β-catenin signaling pathway and promoting the epithelial mesenchymal transition.
    Liu SL; Lin HX; Lin CY; Sun XQ; Ye LP; Qiu F; Wen W; Hua X; Wu XQ; Li J; Song LB; Guo L
    Cancer Lett; 2017 Aug; 402():117-130. PubMed ID: 28583847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin.
    Chan KC; Chan LS; Ip JC; Lo C; Yip TT; Ngan RK; Wong RN; Lo KW; Ng WT; Lee AW; Tsao GS; Kahn M; Lung ML; Mak NK
    Sci Rep; 2015 Apr; 5():9979. PubMed ID: 25897700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiR-34c downregulation leads to SOX4 overexpression and cisplatin resistance in nasopharyngeal carcinoma.
    Bissey PA; Teng M; Law JH; Shi W; Bruce JP; Petit V; Tsao SW; Yip KW; Liu FF
    BMC Cancer; 2020 Jun; 20(1):597. PubMed ID: 32586280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ARC is highly expressed in nasopharyngeal carcinoma and confers X-radiation and cisplatin resistance.
    Wu P; Tang Y; He J; Qi L; Jiang W; Zhao S
    Oncol Rep; 2013 Oct; 30(4):1807-13. PubMed ID: 23877130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/β-catenin/Endothelin-1 axis via activating B cell translocation gene 1.
    Yin P; Song G; Jiang Z
    Cancer Chemother Pharmacol; 2018 May; 81(5):863-872. PubMed ID: 29536130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Caffeic acid phenethyl ester suppressed growth and metastasis of nasopharyngeal carcinoma cells by inactivating the NF-κB pathway.
    Liang Y; Feng G; Wu L; Zhong S; Gao X; Tong Y; Cui W; Qin Y; Xu W; Xiao X; Zhang Z; Huang G; Zhou X
    Drug Des Devel Ther; 2019; 13():1335-1345. PubMed ID: 31118570
    [No Abstract]   [Full Text] [Related]  

  • 31. Design, Synthesis, Molecular Docking, and Tumor Resistance Reversal Activity Evaluation of Matrine Derivative with Thiophene Structure.
    Wei J; Liang Y; Wu L
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33466857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor and radiosensitizing effects of SKLB-163, a novel benzothiazole-2-thiol derivative, on nasopharyngeal carcinoma by affecting the RhoGDI/JNK-1 signaling pathway.
    He J; Cai L; Chen Y; He Y; Wang M; Tang J; Guan H; Wang J; Peng X
    Radiother Oncol; 2018 Oct; 129(1):30-37. PubMed ID: 29519627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma.
    Lo AK; Lung RW; Dawson CW; Young LS; Ko CW; Yeung WW; Kang W; To KF; Lo KW
    J Pathol; 2018 Oct; 246(2):180-190. PubMed ID: 29968360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma.
    Cao JY; Liu L; Chen SP; Zhang X; Mi YJ; Liu ZG; Li MZ; Zhang H; Qian CN; Shao JY; Fu LW; Xia YF; Zeng MS
    Mol Cancer; 2010 Sep; 9():237. PubMed ID: 20828406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crucifera sulforaphane (SFN) inhibits the growth of nasopharyngeal carcinoma through DNA methyltransferase 1 (DNMT1)/Wnt inhibitory factor 1 (WIF1) axis.
    Chen L; Chan LS; Lung HL; Yip TTC; Ngan RKC; Wong JWC; Lo KW; Ng WT; Lee AWM; Tsao GSW; Lung ML; Mak NK
    Phytomedicine; 2019 Oct; 63():153058. PubMed ID: 31394414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts.
    Hu ZY; Zhu XF; Zhong ZD; Sun J; Wang J; Yang D; Zeng YX
    Int J Cancer; 2008 Nov; 123(10):2418-29. PubMed ID: 18712728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LncRNA THOR attenuates cisplatin sensitivity of nasopharyngeal carcinoma cells via enhancing cells stemness.
    Gao L; Cheng XL; Cao H
    Biochimie; 2018 Sep; 152():63-72. PubMed ID: 29959065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo.
    Xue C; Tian Y; Zhang J; Zhao Y; Zhan J; Fang W; Zhang L
    Drug Des Devel Ther; 2016; 10():1173-80. PubMed ID: 27042009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy.
    Wei X; Nian J; Zheng J; He Y; Zeng M
    Cancer Chemother Pharmacol; 2020 May; 85(5):949-957. PubMed ID: 32279103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells.
    Lui VW; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Tsang CM; Lei KI; Chan AT; Mok TS
    Invest New Drugs; 2011 Dec; 29(6):1241-52. PubMed ID: 20571878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.